Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenate dimeglumine
- PMID: 20405242
- DOI: 10.1007/s12029-010-9145-0
Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenate dimeglumine
Abstract
Introduction: The purpose of this paper is to illustrate contrast enhancement patterns of solid focal liver lesions on dynamic and late phase imaging with gadobenate dimeglumine (Gd-BOPTA).
Imaging findings: Unenhanced T2- and T1-weighted, dynamic T1-weighted (arterial, portal-venous, and equilibrium) and late phase (1-3 h) Gd-BOPTA-enhanced MR imaging of different focal liver lesions (nodular regenerative hyperplasia, hepatic adenoma, liver adenomatosis, hepatocellular carcinoma, peripheral cholangiocarcinoma, hypervascular metastases, and hypovascular metastases) are shown. Dynamic imaging was performed using GRE T1-w sequences after the bolus injection of 0.1 mmol/kg Gd-BOPTA; late-phase imaging was obtained at 1-3 h after contrast injection.
Conclusions: Dynamic imaging with Gd-BOPTA provides the same information as with conventional gadolinium-based extracellular contrast agents, while late-phase imaging gives additional information for lesion identification and characterization.
Similar articles
-
Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.Eur J Radiol. 2008 Apr;66(1):65-74. doi: 10.1016/j.ejrad.2007.04.022. Epub 2007 Jun 6. Eur J Radiol. 2008. PMID: 17555901 Clinical Trial.
-
Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.Radiology. 2005 Jul;236(1):166-77. doi: 10.1148/radiol.2361040338. Epub 2005 Jun 13. Radiology. 2005. PMID: 15955857
-
Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.Invest Radiol. 2007 Feb;42(2):105-15. doi: 10.1097/01.rli.0000251539.05400.06. Invest Radiol. 2007. PMID: 17220728 Clinical Trial.
-
Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) as contrast agent for magnetic resonance imaging of the liver: mechanistic studies in animals.J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S169-79. doi: 10.1097/00004728-199911001-00022. J Comput Assist Tomogr. 1999. PMID: 10608413 Review.
-
Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy.Korean J Radiol. 2009 May-Jun;10(3):294-302. doi: 10.3348/kjr.2009.10.3.294. Epub 2009 Apr 22. Korean J Radiol. 2009. PMID: 19412518 Free PMC article. Review.
Cited by
-
Intraindividual crossover comparison of gadobenate dimeglumine-enhanced and gadoxetate disodium-enhanced MRI for characterizing focal liver lesions.Eur Radiol Exp. 2025 Feb 18;9(1):23. doi: 10.1186/s41747-025-00551-8. Eur Radiol Exp. 2025. PMID: 39966271 Free PMC article. Clinical Trial.
-
Low-dose gadobenate dimeglumine-enhanced MRI of the kidney for the differential diagnosis of localized renal lesions.Radiol Med. 2015 Dec;120(12):1100-11. doi: 10.1007/s11547-015-0548-7. Epub 2015 Jun 19. Radiol Med. 2015. PMID: 26088468 Free PMC article.
-
A CT-based radiomics nomogram for differentiation of focal nodular hyperplasia from hepatocellular carcinoma in the non-cirrhotic liver.Cancer Imaging. 2020 Feb 24;20(1):20. doi: 10.1186/s40644-020-00297-z. Cancer Imaging. 2020. PMID: 32093786 Free PMC article.
-
Magnetic Resonanance Imaging of the Liver (Including Biliary Contrast Agents)-Part 2: Protocols for Liver Magnetic Resonanance Imaging and Characterization of Common Focal Liver Lesions.Semin Roentgenol. 2016 Oct;51(4):317-333. doi: 10.1053/j.ro.2016.05.016. Epub 2016 May 30. Semin Roentgenol. 2016. PMID: 27743568 Free PMC article. Review. No abstract available.
-
Hepatic Involvement in Acquired Immunodeficiency Syndrome-Associated Kaposi's Sarcoma: A Descriptive Analysis on CT, MRI, and Ultrasound.Infect Drug Resist. 2024 Mar 18;17:1073-1084. doi: 10.2147/IDR.S440305. eCollection 2024. Infect Drug Resist. 2024. PMID: 38525478 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Medical